RenovoRx to present RenovoGem data at AACR

RenovoRx announced that it will present detailed, open label, planned Phase III interim data analysis of its innovative RenovoGem therapy for pancreatic cancer patients at the American Association for Cancer Research, or AACR. The interim analysis shows a six-month median overall survival benefit for patients. That is nearly a 60% improvement versus the study control arm and current standard of care: intravenous, or IV, administration of gemcitabine and nab-paclitaxel for locally advanced pancreatic cancer, or LAPC. RenovoGem patients also had greater than 65% reduction in adverse events. These can include nausea, fatigue, and a decline in white blood cells.